WARSAW, Poland, June 3, 2026
Ingenix, an emerging artificial intelligence company focused on transforming drug discovery through advanced biological reasoning, has announced the completion of a €13 million seed-extension funding round led by Sofinnova Partners, with participation from Inovo VC and OTB VC. The funding will support the expansion of Ingenix’s proprietary Biological Reasoning Engine, a next-generation AI platform designed to understand and interpret complex biological systems across multiple data modalities. The company also launched its Qualified Access Program, enabling pharmaceutical and biotechnology organizations to collaborate directly with Ingenix on translational research and drug development challenges. The investment highlights growing investor confidence in AI technologies that move beyond conventional machine-learning approaches and focus on delivering actionable scientific insights capable of accelerating therapeutic innovation.
Biological Reasoning Engine Introduces New AI Architecture
At the center of Ingenix’s strategy is its proprietary Modality Fusion architecture, an AI framework designed to integrate biological, chemical, and clinical datasets across multiple biological scales. Unlike traditional AI models that rely primarily on increasing data volume and computational scale, Ingenix believes biology requires specialized reasoning systems capable of understanding complex relationships between diverse biological modalities. The company’s Biological Reasoning Engine combines best-in-class AI models and enables direct reasoning across their representations, allowing researchers to generate mechanistic insights rather than simple pattern recognition outputs.
According to the company, every recommendation generated by the platform includes transparent reasoning pathways, supporting evidence, and scientific caveats, enabling researchers to evaluate conclusions with greater confidence. This approach aims to address one of the most persistent challenges in drug development: translating large amounts of biological data into meaningful therapeutic decisions.
AI Platform Demonstrates Value in Oncology Research
Advertisement
Ingenix highlighted a recent oncology collaboration in which its Biological Reasoning Engine was applied to a complex dual-payload antibody-drug conjugate (ADC) prioritization challenge. The partner biotechnology company faced thousands of potential payload combinations but lacked the resources to experimentally evaluate every possibility. Using first-principles biological reasoning rather than relying solely on historical datasets, the platform generated fifteen candidate combinations for expert review. Independent evaluation showed that several predictions aligned with publicly known hypotheses, others matched unpublished internal findings previously unknown to Ingenix, and multiple novel candidates were identified as actionable opportunities by the partner’s translational science team.
According to the company, the analysis produced insights in minutes that had required years of laboratory research and millions of euros of investment to uncover. The results underscore the potential role of advanced AI systems in accelerating oncology research and improving decision-making throughout the drug development process.
New Funding Supports Expansion Across Pharma and Biotech
The €13 million financing will allow Ingenix to further develop its Biological Reasoning Engine while expanding partnerships with pharmaceutical and biotechnology organizations seeking AI-driven research solutions. The company was founded by AI researchers and engineers from the team behind Applica, the artificial intelligence company acquired by Snowflake in 2022. Members of the founding team contributed to the development of TILT, a language model recognized for its performance on benchmarks associated with GPT-4-level systems. By combining expertise in frontier AI development with experienced pharmaceutical scientists, Ingenix aims to bridge the gap between computational innovation and practical biomedical research. Investors believe that future value in AI-enabled drug development will increasingly depend on systems capable of reasoning across biological complexity rather than simply processing larger datasets.
As demand for more efficient therapeutic discovery continues to grow, Ingenix’s platform may help pharmaceutical companies reduce research timelines, identify novel drug targets, and improve the probability of clinical success. The latest funding round positions the company to accelerate development of its technology and strengthen its role in the rapidly expanding field of AI-powered drug discovery and precision medicine innovation.
Source: Ingenix, Sofinnova Partners press release
